Install Free Gold Price Widget!
Install Free Gold Price Widget!
Install Free Gold Price Widget!
|
- ONC201 TIC10 enhances durability of mTOR inhibitor everolimus in . . .
The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC) However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inhibitor effectiveness
- The therapeutic potential of mTOR inhibitors in breast cancer
The effects of combining the PI3K inhibitor pilaralisib or the PI3K mTOR dual inhibitor voxtalisib with letrozole has been examined in phase I II clinical trials in HR+, HER2− breast cancers that were refractory to nonsteroidal AI therapy
- Development of novel agents for the treatment of early estrogen . . .
Here we review the clinical investigation of targeted and novel therapies, including inhibitors of the PI3K-AKT-mTOR pathway, oral selective estrogen receptor degraders (SERDs), and PARP-inhibitors for the treatment of early ER+ breast cancer
- mTOR inhibitors in the management of hormone receptor-positive breast . . .
This review will focus on the management of HR-positive breast cancer (BC), the current standard of care, and the new evidence on use of mammalian target of rapamycin (mTOR) inhibitors in this setting
- Current status of PI3K-mTOR inhibition in hormone-receptor positive . . .
For this reason, dual inhibition of the pathway by targeting mTORC1 2 proteins have been tested (Table (Table1), 1), and some phase 1 studies are exploring new PI3K inhibitors, such as gedatolisib (NCT02626507) in neoadjuvant setting for ER+, HER2- BC patients
- ONC201 TIC10 enhances durability of mTOR inhibitor everolimus . . . - eLife
Abstract The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC) However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inhibitor effectiveness
- Targeting the mTOR pathway in breast cancer - SAGE Journals
For BC in particular, endocrine therapies such as the selective estrogen receptor (ER) modulator, tamoxifen, antagonize ER in estrogen receptor–positive (ER+) cancers while the humanized monoclonal antibody, trastuzumab, inhibits receptor signaling in HER2− amplified overex-pressing cancers 3–7 Each therapy achieves a relatively high response ra
- Current medical treatment of estrogen receptor-positive breast cancer - PMC
The addition of an mTOR inhibitor (everolimus) to examestane in patients with ER+ BC and advanced disease refractory to both SERMs and AIs, can improve the progression-free survival (PFS) compared to everolimus alone
|
|
|